Cargando…

Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy

OBJECTIVES: Wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM) is a progressive and fatal condition. Although prognosis can be determined at the time of diagnosis according to National Amyloidosis Centre (NAC) transthyretin amyloidosis (ATTR) stage, the clinical course varies substantially b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Law, Steven, Petrie, Aviva, Chacko, Liza, Cohen, Oliver C, Ravichandran, Sriram, Gilbertson, Janet A, Rowczenio, Dorota, Wechalekar, Ashutosh D, Martinez-Naharro, Ana, Lachmann, Helen J, Whelan, Carol J, Hutt, David F, Hawkins, Philip N, Fontana, Marianna, Gillmore, Julian D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Heart Failure and Cardiomyopathies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899483/ https://www.ncbi.nlm.nih.gov/pubmed/33990410 http://dx.doi.org/10.1136/heartjnl-2021-319063

Ejemplares similares

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020)

Superiority of proatrial natriuretic peptide in the prognostic power in patients with acute decompensated heart failure on hospital admission: comparison with B-type natriuretic peptide and other natriuretic peptide forms
por: Takashio, Seiji, et al.
Publicado: (2019)

Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden
por: Lauppe, Rosa Elisabeth, et al.
Publicado: (2021)

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis
por: Law, Steven, et al.
Publicado: (2022)

Improvements of predictive power of B-type natriuretic peptide on admission by mathematically estimating its discharge levels in hospitalised patients with acute heart failure
por: Anegawa, Eiji, et al.
Publicado: (2021)

A COMBINED APPROACH USING HIGH-SENSITIVE TROPONIN I AND N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE FOR RISK STRATIFICATION IN PATIENTS WITH CORONAVIRUS DISEASE 2019
por: Sano, Madoka, et al.
Publicado: (2023)

US CARDIOLOGIST AND PATIENT PERSPECTIVES ON COVID-19 TELEHEALTH PRACTICES FOR PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
por: Mitter, Sumeet, et al.
Publicado: (2021)

Essential components in natriuretic peptide-guided management of heart failure: an intervention synthesis
por: Oke, Jason, et al.
Publicado: (2018)

Natriuretic peptide level at heart failure diagnosis and risk of hospitalisation and death in England 2004–2018
por: Taylor, Clare J, et al.
Publicado: (2022)

Role of N-terminal pro-B type natriuretic peptide as a predictor of poor outcomes in patients with HFrEF receiving primary prevention implantable cardioverter-defibrillator therapy: a systematic review and dose–response meta-analysis
por: Prameswari, Hawani Sasmaya, et al.
Publicado: (2023)

Value of natriuretic peptides and tissue Doppler imaging in the estimation of left ventricular filling pressure in patients with cardiac amyloidosis
por: Brun, Stéphanie, et al.
Publicado: (2019)

Diagnostic yield of a heart failure referral pathway using N-terminal pro-brain natriuretic peptide
por: Zegard, Abbasin, et al.
Publicado: (2023)

Prognostic significance of repeated brain natriuretic peptide measurements after percutaneous transluminal septal myocardial ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy
por: Akita, Keitaro, et al.
Publicado: (2018)

Left ventricular diastolic reserve in patients with type 2 diabetes mellitus
por: Leung, Melissa, et al.
Publicado: (2015)

Endothelial function and left ventricular diastolic functional reserve in type 2 diabetes mellitus
por: Leung, Melissa, et al.
Publicado: (2014)

Contemporary risk estimates of three HbA(1c) variables in relation to heart failure following diagnosis of type 2 diabetes
por: Skrtic, Stanko, et al.
Publicado: (2017)

Ferumoxytol-enhanced MRI in patients with prior cardiac transplantation
por: Stirrat, Colin G, et al.
Publicado: (2019)

Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure
por: Mealing, Stuart, et al.
Publicado: (2016)

Individual patient data network meta-analysis of mortality effects of implantable cardiac devices
por: Woods, B, et al.
Publicado: (2015)

Rationale and design of a randomised trial of intravenous iron in patients with heart failure
por: Kalra, Paul R, et al.
Publicado: (2022)

Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis
por: Patel, Rishi K., et al.
Publicado: (2022)

Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates
por: Janoušek, J, et al.
Publicado: (2009)

Prospective development and validation of a model to predict heart failure hospitalisation
por: Cubbon, R M, et al.
Publicado: (2014)

Inflammation and echocardiographic parameters of ventricular hypertrophy in a cohort with preserved cardiac function
por: Medenwald, D, et al.
Publicado: (2014)

Trends in left ventricular assist device use and outcomes among Medicare beneficiaries, 2004–2011
por: Lampropulos, Julianna F, et al.
Publicado: (2014)

Vitamin D levels and left ventricular diastolic function
por: Pandit, Anil, et al.
Publicado: (2014)

Novel cardiac pacemaker-based human model of periodic breathing to develop real-time, pre-emptive technology for carbon dioxide stabilisation
por: Baruah, Resham, et al.
Publicado: (2014)

Functional, morphological and electrocardiographical abnormalities in patients with apical hypertrophic cardiomyopathy and apical aneurysm: correlation with cardiac MR
por: Suwa, Kenichiro, et al.
Publicado: (2014)

ECG characteristics according to the presence of late gadolinium enhancement on cardiac MRI in hypertrophic cardiomyopathy
por: Grall, Sylvain, et al.
Publicado: (2014)

Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms
por: Lee, Dawn, et al.
Publicado: (2014)

Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study
por: Chow, V, et al.
Publicado: (2014)

Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy
por: Wasielewski, Marijke, et al.
Publicado: (2014)

The influence of aortoseptal angulation on provocable left ventricular outflow tract obstruction in hypertrophic cardiomyopathy
por: Critoph, Christopher Howell, et al.
Publicado: (2014)

In-hospital treatment and outcomes of heart failure in specialist and non-specialist services: a retrospective cohort study in the elderly
por: Parmar, Kishan R, et al.
Publicado: (2015)

Predictors and prognostic value of left atrial remodelling after acute myocardial infarction
por: Kyhl, Kasper, et al.
Publicado: (2015)

Clinical prediction of incident heart failure risk: a systematic review and meta-analysis
por: Yang, Hong, et al.
Publicado: (2015)

Mechanical dyssynchrony is additive to ECG criteria and independently associated with reverse remodelling and clinical response to cardiac resynchronisation therapy in patients with advanced heart failure
por: Bank, Alan J, et al.
Publicado: (2015)

Prognostic impact of blood pressure response plus gadolinium enhancement in dilated cardiomyopathy
por: Tateishi, Emi, et al.
Publicado: (2015)

The role of cardiac biomarkers for predicting left ventricular dysfunction and cardiovascular mortality in acute exacerbations of COPD
por: Buchan, Alice, et al.
Publicado: (2015)

Ischaemia change with revascularisation versus medical therapy in reduced ejection fraction
por: Mentz, Robert J, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rgruismt3na71sr81q5ro2o5a6